vs
Side-by-side financial comparison of Diversified Energy Co (DEC) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
Diversified Energy Co is the larger business by last-quarter revenue ($666.5M vs $598.7M, roughly 1.1× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 29.3%, a 11.5% gap on every dollar of revenue. EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $280.0M).
DTE Energy is a Detroit-based diversified energy company involved in the development and management of energy-related businesses and services in the United States and Canada. Its operating units include an electric utility serving 2.2 million customers and a natural gas utility serving 1.3 million customers in Michigan.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
DEC vs EXEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $666.5M | $598.7M |
| Net Profit | $195.5M | $244.5M |
| Gross Margin | — | 95.6% |
| Operating Margin | 37.6% | 39.3% |
| Net Margin | 29.3% | 40.8% |
| Revenue YoY | — | 5.6% |
| Net Profit YoY | — | 74.8% |
| EPS (diluted) | — | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $598.7M | ||
| Q4 25 | $666.5M | $597.8M | ||
| Q3 25 | $499.8M | $568.3M | ||
| Q2 25 | $600.3M | $555.4M | ||
| Q1 25 | — | $566.8M | ||
| Q3 24 | — | $539.5M | ||
| Q2 24 | — | $637.2M | ||
| Q1 24 | — | $425.2M |
| Q1 26 | — | $244.5M | ||
| Q4 25 | $195.5M | $193.6M | ||
| Q3 25 | $171.1M | $184.8M | ||
| Q2 25 | $297.7M | $159.6M | ||
| Q1 25 | — | $139.9M | ||
| Q3 24 | — | $118.0M | ||
| Q2 24 | — | $226.1M | ||
| Q1 24 | — | $37.3M |
| Q1 26 | — | 95.6% | ||
| Q4 25 | — | 96.9% | ||
| Q3 25 | — | 96.6% | ||
| Q2 25 | 44.7% | 96.5% | ||
| Q1 25 | — | 96.5% | ||
| Q3 24 | — | 96.8% | ||
| Q2 24 | — | 97.2% | ||
| Q1 24 | — | 95.0% |
| Q1 26 | — | 39.3% | ||
| Q4 25 | 37.6% | 39.6% | ||
| Q3 25 | 36.2% | 37.6% | ||
| Q2 25 | 48.5% | 33.6% | ||
| Q1 25 | — | 28.8% | ||
| Q3 24 | — | 25.2% | ||
| Q2 24 | — | 43.3% | ||
| Q1 24 | — | 6.9% |
| Q1 26 | — | 40.8% | ||
| Q4 25 | 29.3% | 32.4% | ||
| Q3 25 | 34.2% | 32.5% | ||
| Q2 25 | 49.6% | 28.7% | ||
| Q1 25 | — | 24.7% | ||
| Q3 24 | — | 21.9% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 8.8% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | — | $0.69 | ||
| Q3 25 | $2.14 | $0.65 | ||
| Q2 25 | $3.67 | $0.55 | ||
| Q1 25 | — | $0.47 | ||
| Q3 24 | — | $0.40 | ||
| Q2 24 | — | $0.77 | ||
| Q1 24 | — | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.7M | $1.1B |
| Total DebtLower is stronger | $2.7B | — |
| Stockholders' EquityBook value | $984.1M | $2.2B |
| Total Assets | $6.2B | $2.8B |
| Debt / EquityLower = less leverage | 2.76× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.1B | ||
| Q4 25 | $29.7M | $988.5M | ||
| Q3 25 | — | $791.1M | ||
| Q2 25 | $23.7M | $1.0B | ||
| Q1 25 | — | $1.1B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $963.3M |
| Q1 26 | — | — | ||
| Q4 25 | $2.7B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $984.1M | $2.2B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | $727.7M | $2.1B | ||
| Q1 25 | — | $2.2B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.1B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $6.2B | $2.8B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | $5.7B | $2.8B | ||
| Q1 25 | — | $2.9B | ||
| Q3 24 | — | $3.0B | ||
| Q2 24 | — | $2.8B | ||
| Q1 24 | — | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | 2.76× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $464.6M | $333.5M |
| Free Cash FlowOCF − Capex | $280.0M | $332.4M |
| FCF MarginFCF / Revenue | 42.0% | 55.5% |
| Capex IntensityCapex / Revenue | 27.7% | 0.2% |
| Cash ConversionOCF / Net Profit | 2.38× | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | — | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | $464.6M | $290.3M | ||
| Q3 25 | — | $49.0M | ||
| Q2 25 | $264.1M | $211.4M | ||
| Q1 25 | — | $240.3M | ||
| Q3 24 | — | $271.3M | ||
| Q2 24 | — | $119.5M | ||
| Q1 24 | — | $68.8M |
| Q1 26 | — | $332.4M | ||
| Q4 25 | $280.0M | $288.8M | ||
| Q3 25 | — | $46.2M | ||
| Q2 25 | — | $208.5M | ||
| Q1 25 | — | $236.3M | ||
| Q3 24 | — | $263.1M | ||
| Q2 24 | — | $113.0M | ||
| Q1 24 | — | $59.1M |
| Q1 26 | — | 55.5% | ||
| Q4 25 | 42.0% | 48.3% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 41.7% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 17.7% | ||
| Q1 24 | — | 13.9% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | 27.7% | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.7% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 2.3% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | 2.38× | 1.50× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | 0.89× | 1.32× | ||
| Q1 25 | — | 1.72× | ||
| Q3 24 | — | 2.30× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 1.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DEC
Segment breakdown not available.
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
